The announcement by President Donald Trump’s administration of the results of a probe into pharmaceutical imports and new sector-specific tariffs are likely “weeks away,” which would be later than initially promised, reported Reuters, citing official and industry sources. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Trump, pharma industry discuss increasing medicine spending abroad, Reuters says
- Trump Weekly: President says raising tariffs on India ‘substantially’
- Trump says separate tariff announcements coming for semi chips, pharmaceuticals
- Trump posts letters calling on drug company CEOs to lower prices
- Press Secretary says Trump sent letters today to pharmaceutical companies